Long-term safety evaluation of Daxocox ® tablets (enflicoxib) in dogs after weekly oral administrations for seven months

Daxocox ® [Ecuphar/Animalcare Group] contains the selective COX-2 inhibitor enflicoxib, approved in the EU for the treatment of pain and inflammation associated with osteoarthritis in dogs. The safety of Daxocox® ...

Source: BMC Veterinary Research - June 3, 2021 Category: Veterinary Research Authors: Josep Homedes, Marta Salichs and Antonio Guzman Tags: Research Source Type: research